

# Preventing Complications: The Biological and Functional Success of Anti-Reflux Needleless Connectors

Bob Buzas RPh<sup>1</sup>, Nancy Moureau PhD RN, CRNI, CPUI, VA-BC<sup>2</sup>, S. Matthew Gibson BS, CRNI, VA-BC<sup>3</sup>, Michael Buzas, BSBME<sup>4</sup>

<sup>1</sup>Allegheny Health Network Home Infusion, Pittsburgh, PA, <sup>2</sup>PICC Excellence, Inc, Hartwell, GA, <sup>3</sup>Vascular Access Consulting, Henderson, KY, <sup>4</sup>Nexus Medical, LLC, Lenexa, KS

## BACKGROUND

In a previous quality improvement study with data from nearly 500,000 patient days, it was demonstrated that switching from a non-anti-reflux needleless connector (NC) to an anti-reflux connector produced:

- 48% reduction in tPA usage,
- 66% reduction in ER visits,
- 27% fewer patient encounters for clotted catheters,
- savings of more than \$100,000 on tPA, nursing expenses and items related to treating the occlusion<sup>1</sup>.

This current research examines the root cause of catheter occlusions and the function of neutral anti-reflux NCs. Blood is often the first body fluid that comes into contact with IV catheters. Interactions between blood and IV catheter material trigger a complex series of events including protein adsorption, platelet adhesion and activation, coagulation, and thrombosis. These biological reactions necessitate using anti-reflux technology that decreases the risk of occlusions and central line-associated bloodstream infections (CLABSI).


## PURPOSE

The purpose of this research was to study the clinical, biological and functional differences between anti-reflux needleless connectors and connectors without anti-reflux capabilities. Our hypothesis is that these past results were due to switching to an anti-reflux needleless connector that minimized blood proteins within the inner surface of the IV catheter, thereby preventing biological reactions that led to thrombus formation.

## METHODS

Two in-vitro simulation studies examined how anti-reflux and non-anti-reflux NCs performed using IV containers with green and clear water.

- Test #1 simulated pressure changes by observing fluid movement between IV bags. This was accomplished by elevating an IV bag with dyed fluid 2 inches above a clear bag.
- Test #2 used a venous simulation manometer (figure 1) measured fluid reflux or displacement upon syringe connection and disconnection. Negative and positive fluid displacement represent reflux into the catheter and aspiration towards the patient.



**Figure 1:** Venous Simulator;  
A – 10 mL BD Luer Lock Syringe,  
B – NC Unit Under Test,  
C – Stopcock,  
D – Glass rod beside metric ruler,  
E – Output to reservoir bag


## RESULTS

These two tests indicate anti-reflux technology can reduce uncontrolled blood reflux into IV catheters upon pressure changes, connection and disconnection.

- Test #1 showed anti-reflux NCs were able to stop blood reflux when pressure changes occurred in the closed IV system, while non-anti-reflux NCs were not able to prevent bi-directional fluid movement.
- Test #2 demonstrated the anti-reflux NCs had the lowest amount of reflux upon both connection and disconnection.

## DISCUSSION

The results demonstrate that anti-reflux NCs may significantly reduce the amount of blood reflux upon disconnection of a syringe compared to NCs without anti-reflux technology ( $p < 0.0001$ ). It is reasonable to hypothesize that increased volumes of blood reflux will lead to increased risk of intraluminal thrombotic catheter occlusions and bloodstream infections<sup>2</sup>. This is important for home infusion clinicians because, as demonstrated in the previous study, occlusions decrease nursing efficiency and increase costs associated with the treatment of occlusions and CLABSI<sup>1</sup>.




**Figure 2:** Foreign body response following blood contact to IV catheter material leading to intraluminal thrombotic catheter occlusions

The body's natural biological response to foreign materials is to form a protective layer of plasma proteins. When an IV catheter enters the vein, the layer of plasma proteins instantly adsorbs to the intraluminal surfaces, which forms a biofilm that attracts platelets and clotting factors<sup>3, 4, 5, 6, 7, 8</sup>. (Figure 2) This biological reaction continues to form a fibrin mesh that traps blood cells and promotes thrombus formation within the catheter<sup>2</sup>.


Bacteria can enter and contaminate IV catheters from skin-surface organisms that migrate into the blood stream, contaminated catheter hubs, NCs, infusate, and via an existing distant infection<sup>4, 5, 10, 11</sup>. Bacteria can bind to the protein coated surfaces described above, which then proliferate the highly antibiotic-resistant biofilm<sup>12, 13</sup>. (Figure 3 & 4)

## DISCUSSION (cont'd)

The biofilm can break away naturally or by the intervention of flushing or use of thrombolytics. Harmful infections can happen once biofilm enters the bloodstream<sup>14, 15, 16, 17</sup>. The infection risk increases by 2.87 to 3.59 times when thrombolytics are used on intraluminal catheter occlusions<sup>14, 15, 18</sup>.



**Figure 3:** Top: Contrasts in pathways of bacteria entry leading to catheter-related bloodstream infections. Bottom: Schematic of microbial ingress leading to attachment to the blood protein conditioning film, biofilm formation and detachment.



**Figure 4:** Mechanism of action of tPA causing the intraluminal thrombotic catheter occlusion dissolve and the bacteria to enter the bloodstream.

## CONCLUSION

This research demonstrates anti-reflux devices function differently than other commercially available NCs. Anti-reflux NCs control bi-directional fluid movement and greatly inhibit blood reflux which prevented occlusions in the home infusion setting. Reducing occlusions has been shown to also cut down on nursing visits, tPA use, costs associated to provide tPA in the home, delays in treatment, ER visits, treatment of CLABSI and potentially placement of new IV access. The use of anti-reflux NCs support the treatment of the patient and not a complication from treating the patient.

## DISCLOSURES

Bob Buzas: Consultant, Nexus Medical  
Nancy Moureau: Consultant, Nexus Medical  
S. Matthew Gibson: Consultant, Nexus Medical  
Michael Buzas: Consultant, Nexus Medical

## REFERENCES

1. Buzas, B. "Keeping You Connected: Anti-Reflux Connectors Reduce Catheter Occlusions and Use of Alteplase." Presented at the National Home Infusion Association 2021 Annual Conference. [https://nexusmedical.com/wp-content/uploads/2021/05/BuzasNHIA2021\\_FINAL-Poster.pdf](https://nexusmedical.com/wp-content/uploads/2021/05/BuzasNHIA2021_FINAL-Poster.pdf).
2. Hunter, H. et al. Impact of Blood Reflux in the Incidence of Catheter Occlusions: A Controlled Experimental Study. Presented at the Association for Vascular Access Annual Scientific Meeting, San Antonio, Texas, 2012.
3. Xu, Li-Chang, et al. "Proteins, Platelets, and Blood Coagulation at Biomaterial Interfaces." *Colloids and Surfaces B: Biointerfaces*, vol. 124, 2014, pp. 49-65, doi:10.1016/j.colsurfb.2014.09.040.
4. Neoh, Koon Gee, et al. "Surface Modification Strategies for Combating Catheter-Related Complications: Recent Advances and Challenges." *Journal of Materials Chemistry B*, vol. 5, no. 11, 2017, pp. 2045-2067, doi:10.1039/c6tb02300g.
5. Farrell, D.H., and P. Thiagarajan. "Binding of Recombinant Fibrinogen Mutants to Platelets." *Journal of Biological Chemistry*, vol. 269, no. 1, 1994, pp. 226-231, doi:10.1093/jbc/269.1.226-231.
6. Grunhewer, J. M., et al. "Platelet Adhesion and Procoagulant Activity Induced by Contact with Radiofrequency Glow Discharge Polymers: Roles of Adsorbed Fibrinogen and vWF." *Journal of Biomedical Materials Research*, vol. 51, no. 4, 2000, pp. 569-579, doi:10.1002/jbm.b.46362.2000.01951514-4-669-aid-jbm.b53.0.co2-4.
7. Jaffer, I. H., et al. "Medical Device-Induced Thrombosis: What Causes It and How Can We Prevent It?" *Journal of Thrombosis and Haemostasis*, vol. 13, 2015, doi:10.1111/jth.12968.
8. Siskin, Jacquelyn L, et al. "Management of Occlusion and Thrombosis Associated with Long-Term Indwelling Central Venous Catheters." *The Lancet*, vol. 374, no. 9684, 2009, pp. 159-169, doi:10.1016/S0140-6736(09)02203-8.
9. Mermel, Leonard A. "Prevention of Intravascular Catheter-Related Infections." *Annals of Internal Medicine*, vol. 132, no. 5, 2000, p. 391, doi:10.7326/0005-4995-132-5-200003070-00009.
10. Mermel, L. A. "What Is the Predominant Source of Intravascular Catheter Infections?" *Clinical Infectious Diseases*, vol. 52, no. 2, 2010, pp. 211-212, doi:10.1093/cid/ciq108.
11. Salfar, Nasim, and Dennis G. Haid. "The Pathogenesis of Catheter-Related Bloodstream Infection with Noncuffed Short-Term Central Venous Catheters." *Intensive Care Medicine*, vol. 30, no. 1, 2004, pp. 62-67, doi:10.1007/s0054-003-2045-z.
12. Katsikoglou, M., and V.F. Hissirli. "Concise Review of Mechanisms of Bacterial Adhesion to Biomaterials and of Techniques Used in Estimating Bacteria-Material Interactions." *European Cells and Materials*, vol. 8, 2004, pp. 37-57, doi:10.22203/eum.v08i02.
13. Sharma, Divakar, et al. "Antibiotics versus Biofilm: An Emerging Battleground in Microbial Communities." *Antimicrobial Resistance & Infection Control*, vol. 5, no. 1, 2012, doi:10.1186/1745-017-012-033-3.
14. Rowan, Courtney M., et al. "Alteplase Use for Malfunctioning Central Venous Catheters Correlates With Catheter-Associated Bloodstream Infections." *Pediatric Critical Care Medicine*, vol. 14, no. 3, 2013, pp. 305-309, doi:10.1007/s00130-013-0278-8.
15. Thakkar, Kiran, et al. "The Role of Tissue Plasminogen Activator Use and Systemic Hypercoagulability in Central Line-Associated Bloodstream Infections." *American Journal of Infection Control*, vol. 42, no. 4, 2014, pp. 417-420, doi:10.1016/j.ajic.2013.03.015.
16. Refluette, Fany, et al. "Staphylococcus Aureus Biofilms and Their Impact on the Medical Field." *The Rise of Virulence and Antibiotic Resistance in Staphylococcus Aureus*, 2017, doi:10.5772/66380.
17. Zhu, Lei, et al. "Mechanism of Pulsatile Pushing Technique for Soline Injection via a Peripheral Intravenous Catheter." *Clinical Biomechanics*, vol. 80, 2020, p. 105103, doi:10.1016/j.clinbiomech.2020.105103.
18. Alkufly, T., Hansley, S., Khuder, S., Lulu, N., Ruzieh, M., & Duggan, J. (2020). PICC line associated blood stream infections: an analysis of host and device factors. *Translation: The University of Toledo Journal of Medical Sciences*, 8. Retrieved from <https://openjournals.utoledo.edu/index.php/translation/article/view/347>